Pharmaco-metabolomics opportunities in drug development and clinical research

被引:7
作者
Phapale, Prasad [1 ]
机构
[1] European Mol Biol Lab, Metabol Core Facil, Heidelberg, Germany
来源
ANALYTICAL SCIENCE ADVANCES | 2021年 / 2卷 / 11-12期
关键词
clinical research; drug development; drug response; high-resolution mass spectrometry; Indian Pharma; LC-MS; MS; metabolomics; personalised medicine; pharmacokinetics; Pharmaco-metabolomics; triple quadrupole mass spectrometry;
D O I
10.1002/ansa.202000178
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Pharmaco-metabolomics uses metabolic phenotypes for the prediction of inter-individual variations in drug response and helps in understanding the mechanisms of drug action. The field has made significant progress over the last 14 years with numerous studies providing clinical evidence for personalised medicine. However, discovered pharmaco-metabolomic biomarkers are not yet translated into clinics due to a lack of large-scale validation. Integration of targeted and untargeted metabolomics workflows into pharmacokinetic analysis and drug development can advance the field from bench to bedside. Also, Indian pharmaceutical research and its bioanalytical infrastructure are in a position to take on these opportunities by addressing challenges such as appropriate training and regulatory compliance.
引用
收藏
页码:611 / 616
页数:6
相关论文
共 40 条
  • [1] Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine
    Backshall, Alexandra
    Sharma, Rohini
    Clarke, Stephen J.
    Keun, Hector C.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (09) : 3019 - 3028
  • [2] Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
    Beger, Richard D.
    Schmidt, Michael A.
    Kaddurah-Daouk, Rima
    [J]. METABOLITES, 2020, 10 (04)
  • [3] Metabolomics enables precision medicine: "A White Paper, Community Perspective"
    Beger, Richard D.
    Dunn, Warwick
    Schmidt, Michael A.
    Gross, Steven S.
    Kirwan, Jennifer A.
    Cascante, Marta
    Brennan, Lorraine
    Wishart, David S.
    Oresic, Matej
    Hankemeier, Thomas
    Broadhurst, David I.
    Lane, Andrew N.
    Suhre, Karsten
    Kastenmueller, Gabi
    Sumner, Susan J.
    Thiele, Ines
    Fiehn, Oliver
    Kaddurah-Daouk, Rima
    [J]. METABOLOMICS, 2016, 12 (09)
  • [4] Caldwell GW, 2017, CURR TOP MED CHEM, V17, P2716, DOI 10.2174/1568026617666170707130032
  • [5] Center for Drug Evaluation and Research, Table of Pharmacogenomic Biomarkers
  • [6] Central Drugs Standard Control Organization, BA/BE
  • [7] Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism
    Clayton, T. Andrew
    Baker, David
    Lindon, John C.
    Everett, Jeremy R.
    Nicholson, Jeremy K.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (34) : 14728 - 14733
  • [8] Pharmaco-metabonomic phenotyping and personalized drug treatment
    Clayton, TA
    Lindon, JC
    Cloarec, O
    Antti, H
    Charuel, C
    Hanton, G
    Provost, JP
    Le Net, JL
    Baker, D
    Walley, RJ
    Everett, JR
    Nicholson, JK
    [J]. NATURE, 2006, 440 (7087) : 1073 - 1077
  • [9] Das TR., 2016, Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges, P99
  • [10] Metabolomics in epidemiology: from metabolite concentrations to integrative reaction networks
    Fearnley, Liam G.
    Inouye, Michael
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2016, 45 (05) : 1319 - 1328